Mineralys Therapeutics, Inc. announced an underwriting agreement on September 2, 2025, to sell 9,803,921 shares of common stock at $25.50 per share, aiming to raise approximately $234.7 million after expenses. The offering is set to close on September 4, 2025, with a potential for up to 1,470,588 additional shares if underwriters exercise their option.